News Release

Comparison of uptake, prices of biosimilars in the US, Germany, Switzerland

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: The findings of this study suggest that more biosimilars have been marketed in Germany and Switzerland than in the United States. Policies that counter anticompetitive practices in the United States could allow biosimilars to enter the market sooner and could also lower health care costs with improved access. Awareness of biosimilars should be promoted to increase uptake of biosimilars globally. 

Authors: Kerstin N. Vokinger, M.D., J.D., Ph.D., L.L.M., of the University of Zurich in Zurich, Switzerland, is the corresponding author. 

 To access the embargoed study: Visit our For The Media website at this link


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.